Biogen Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Hello, everyone. Pleasure to have Biogen management join us right after Merck. And there's a lot to talk about, but let me turn it over to you, Mike, to kick things off.
Excellent. Thank you very much, Umer, and thank you for having us today, and thank you to everyone for joining us. Priya and I are very happy to be with you.
Before we begin, I do want to just point out that we -- Priya and I will be making some forward-looking statements, and those are based on current expectations and believe actual results could differ, and I would encourage you to refer to our risk factors in our SEC filings.
Here at Biogen, we're very focused on executing and delivering the best results that we can. We last reported in October. And at that time, we raised our guidance on both the top line and the bottom line for the second time this year. Our guidance back in October was on the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |